Contrast Enhanced Spectral Mammography (CESM) Study

Breast Cancer Clinical Trial

— CONTEND  

Official title:

An Assessment of the Impact of CONTrast ENhanceD Mammography (CESM) on Patient Management and Comparison With MRI (CONTEND Study)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02479100
• Other study ID #: RADIOL/2015/CONTEND
• Status: Active, not recruiting
• Phase: N/A
• Start date: March 22, 2016
• Est. completion date: December 31, 2022

Study information

• Verified date: August 2021
• Source: Cambridge University Hospitals NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to determine if the addition of Contrast Enhanced Spectral Mammography (CESM) to standard diagnostic imaging, results in a decision regarding patient management - discharge, follow-up, surgery or treatment - being made sooner than it would if the patient had followed the standard course of investigations and review.

Description:

Women with suspicious breast lesions following mammography and ultrasound will be eligible for the study. Those who consent to participate will be randomised either to receive Contrast Enhanced Spectral Mammography (CESM) in addition to standard care or to receive standard care alone.

Women randomised to receive CESM will undergo the procedure either during the same visit or if necessary on another date within a week. Any additional suspicious lesions detected by CESM will be biopsied along with the original lesion either under ultrasound or x-ray guidance. Biopsy of suspicious lesions is standard care and not part of the research protocol. Those randomised to receive standard care will undergo ultrasound or x-ray guided biopsy of any suspicious lesion identified by ultrasound or mammography.

Results of all biopsies will be discussed at the next multidisciplinary (MDT) meeting where a treatment decision (conservation surgery, mastectomy or neoadjuvent therapy) will be made for those with confirmed disease. MRI will be performed on appropriate women in line with standard practice. Additional disease detected by MRI will be biopsied, either under ultrasound or MRI guidance, if this will influence patient management. The results from these cases will be discussed at the next MDT meeting.

For those women in either arm of the study with benign biopsy results standard care will be followed.

A proforma will be used to record patient pathway, biopsy results and MDT patient management decisions for each case.

For women who received both CESM and MRI, a retrospective review of these images will be made in order to compare diagnostic accuracy. Images from each imaging modality will be read by a different reader for each case. CESM images will be read without the knowledge of MRI results and vice versa. A proforma will be completed by readers to record findings.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 103
• Est. completion date: December 31, 2022
• Est. primary completion date: March 31, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Be willing and able to give written informed consent for participation in the study.

• Have a lesion of suspicion 3, 4 or 5 following mammography and ultrasound.

Exclusion Criteria:

• Known or suspected pregnancyBreast implant

• Previous breast cancer

• Known renal impairment

• History of anaphylactoid or anaphylactic reaction to any contrast media

• Contrast media within 24 hours prior to CESM

• Commencement of neo-adjuvant chemotherapy, hormone treatment, radiotherapy or surgery for this episode

Related Conditions & MeSH terms

• Breast Cancer

Intervention

Diagnostic Test:
• Contrast Enhanced Spectral Mammogram
Undergo a Contrast Enhanced Spectral Mammogram in additional to standard of care

Locations

Country	Name	City	State
United Kingdom	Cambridge University Hospitals NHS Foundation Trust	Cambridge	Cambridgeshire

Sponsors (3)

Lead Sponsor	Collaborator
Cambridge University Hospitals NHS Foundation Trust	GE Healthcare, University of Cambridge

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of impact the addition of CESM has on patient management - does this lead to an earlier diagnosis / treatment plan	The pathway of each participant through the diagnostic process will be reviewed at the end of the data collection period to assess whether the addition of CESM resulted in a definitive decision regarding treatment being made earlier than in the usual diagnostic route.	Retospective analysis at end of data collection period ( approximately I year)